Vivatides Therapeutics, a global biotechnology company focused on developing next-generation RNA therapeutics beyond the liver, has raised $54 million in an oversubscribed Series A financing to accelerate the advancement of its extrahepatic RNA delivery platform and move multiple pipeline programs toward clinical development. The financing underscores growing investor confidence in technologies designed to overcome one of the biggest challenges in RNA medicine—delivering therapeutics effectively to tissues beyond the liver.

The Series A round was co-led by Qiming Venture Partners and a leading industry fund that was not publicly identified. Additional participation came from Highlight Capital and TF Capital, while existing investor Apricot Capital also increased its investment in the company. The proceeds will be used to expand Vivatides’ research and development capabilities, accelerate several therapeutic programs into clinical studies, and strengthen its global research network and team.

Founded in 2025, Vivatides Therapeutics is developing RNA-based medicines designed to target tissues outside the liver, an area widely regarded as one of the next frontiers for RNA therapeutics. While RNA technologies such as small interfering RNA (siRNA) and antisense oligonucleotides have demonstrated significant clinical success in treating liver-associated diseases, expanding these therapies to other organs has remained a major scientific challenge because of the difficulty of delivering RNA molecules precisely to target tissues.

Vivatides aims to address this limitation through proprietary extrahepatic delivery technologies that improve tissue specificity while maintaining therapeutic efficacy. The company is building delivery platforms for both siRNA and antisense oligonucleotide therapeutics, enabling RNA medicines to reach organs and tissues beyond the liver. This capability has the potential to significantly broaden the range of diseases that can be treated using RNA-based approaches.

The company’s research pipeline targets several therapeutic areas where improved RNA delivery could provide new treatment options. According to Vivatides, its programs focus on chronic diseases, including hyperlipidemia, hypertension, metabolic disorders, and oncology. By combining advanced delivery technologies with RNA-based therapeutics, the company seeks to develop medicines capable of addressing diseases that have historically been difficult to treat using conventional drug modalities.

Since its founding, Vivatides has rapidly expanded its scientific platform through advances in ligand conjugation technology, tissue-specific targeting, and delivery efficiency. These innovations are intended to improve the precision with which therapeutic RNA molecules reach intended tissues while minimizing off-target effects. The company believes these delivery capabilities represent a foundational technology that can support multiple therapeutic programs across diverse disease indications.

The newly secured capital will support continued investment in research and development while advancing several lead candidates toward clinical evaluation. In addition to expanding its pipeline, Vivatides plans to strengthen its global operations by growing its research organization and building collaborations that support further development of its RNA delivery technologies. The company maintains operations in both Suzhou, China, and Boston, reflecting its international approach to drug discovery and development.

Investor interest in Vivatides reflects broader momentum across the RNA therapeutics sector, which has experienced substantial growth following advances in gene-silencing technologies and nucleic acid-based medicines. While several RNA therapies have already reached the market for liver-related diseases, companies capable of extending RNA delivery into other tissues are increasingly viewed as addressing one of the industry’s most significant remaining technical barriers.

The successful completion of both seed and Series A financing within approximately a year of the company’s founding highlights the pace at which Vivatides has progressed. Investors have expressed confidence in the company’s platform technology and its potential to generate multiple therapeutic candidates capable of addressing diseases beyond the reach of existing RNA medicines.

With fresh Series A funding in place, Vivatides Therapeutics is positioned to accelerate the development of its extrahepatic RNA therapeutics platform while expanding its scientific capabilities and advancing multiple pipeline programs toward the clinic. As RNA medicines continue to reshape modern drug development, the company aims to establish itself as a leader in delivering next-generation therapies that extend the promise of RNA technology to a broader range of diseases and patients.

Related Articles